Case Studies & Whitepapers2026-10-23
FAQ: Hot-Melt Extrusion Technology Empowers Innovative Drug Development
1. Is ASD development necessary when the API is already amorphous?
A: Based on the experience of Porton's formulation R&D team, a feasibility assessment for ASD development is generally recommended. Although amorphous API exhibits higher solubility, its inherent risks are significant:
a) Physical stability risk:
Lacking the recrystallization inhibition mechanism provided by a polymeric carrier, the amorphous API is prone to recrystallization during storage, which leads to altered disso
More
News
More
Case Studies & Whitepapers2026-09-25
Dual-Payload Conjugates: Addressing the CMC Challenges of a New Therapeutic Approach
Dual-payload conjugates—two mechanistically distinct payloads carried on a single targeting vehicle—represent the next technological frontier beyond conventional ADCs.
Case Studies & Whitepapers2026-09-21
PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
This article offers a systematic overview of PMO drug technology covering underlying principles, manufacturing workflows, and therapeutic prospects.
